A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

Which side has more sex appeal?” This was Maximilian Krah, a highly controversial and outspoken, far-right Alternative for Germany (AfD) politician speaking to CNN in Halle, eastern Germany ...

While Germany's DAX gained 0.1%,... The US Dollar Index (DXY) starts the week lower as market participants reposition ahead of a data-heavy week. EUR/USD recovers but will German inflation derail ...

The inflation rate in Germany is expected to be +2.3% in January 2025. It is measured as the change in the consumer price index (CPI) compared with the same month a year earlier. Based on the results ...

Investing.com - European stock markets edged higher Friday, with investors digesting more corporate earnings as well as regional inflation data after the European Central Bank’s latest easing of ...

The inflation rate in Germany is expected to be +2.3% in January 2025. It is measured as the change in the consumer price index (CPI) compared with the same month a year earlier. Based on the results ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Regeneron's main product is Duxipent, an autoimmune disease drug. It sells Libtayo, a cancer drug that recently got approved for a new medical indication. Both drugs are sold through a partnership ...